Clinical trials: Insulin
- Drug or intervention Insulin
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Diabetes, Diabetes Mellitus, Type 1
Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492218
- Testing
- biphasic human insulin 30
- Where
- Philippines
- Volunteers
- 1,330 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Post Marketing Surveillance Study of Biphasic Insulin Aspart 30
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of biphasic insulin aspart 30 in post-marketing use.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01536613
- Testing
- biphasic insulin aspart 30
- Where
- South Korea
- Volunteers
- 5,346 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
This study aims to evaluate the efficacy and safety of GB06 (a biosimilar of Norditropin®FlexProTM from Novo Nordisk) for the treatment of growth disorders caused by growth hormone deficiency (GHD) in children.
- Conditions
- Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children, Growth Hormone Deficiency, Pediatric
- Trial name
- NCT07553351
- Testing
- GB06, Norditropin®FlexProTM
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Kexing Biopharm Co., Ltd.
Diabetes, Diabetes Mellitus, Type 1
A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes
This study is conducted globally. The aim of this study is to describe the proportion of patients with hypoglycaemic episodes and estimate the incidence of various types of hypoglycaemia in the retrospective and prospective…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02306681
- Testing
- No treatment given
- Where
- 8 sites in Bangladesh, Colombia and 6 more
- Volunteers
- 7,315 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction
This study is conducted in Europe. The aim of this study is to assess the well-being of patients following treatment with insulin detemir (Levemir®) in subjects with type 1 or type 2 diabetes in whom either initiation of or a…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- CONFIDENCE (NCT01542476)
- Testing
- insulin detemir
- Where
- Netherlands
- Volunteers
- 299 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)
- Trial name
- NCT00527397
- Testing
- CP-464,005
- Where
- 10 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes
This observational study is conducted in Europe. The trial aims to observe the incidence of serious adverse drug reactions in children and adolescents with type 1 diabetes during Levemir® treatment.
- Trial name
- PREDICTIVE™ (NCT00704574)
- Testing
- insulin detemir
- Where
- Sweden
- Volunteers
- 159 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Special Survey for Patients With Type 1 or Type 2 Diabetes
This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia under normal clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01538589
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 1,582 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Special Survey of Production of Insulin Aspart Specific Antibody
This study is conducted in Japan. The aim of this study is to collect data of production of insulin aspart specific antibody under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01487369
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 204 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin…
- Trial name
- NCT01065766
- Testing
- Sitagliptin/metformin
- Volunteers
- 4,065 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Performance Study of the SOLO 2.0 Insulin Pump
The Purpose of the study is to to evaluate the performance of the SOLO (version 2.0) micropump insulin delivery system, in Type 1 diabetic patients who use insulin pumps for their treatment.
- Trial name
- NCT01500928
- Testing
- SOLO insulin pump
- Where
- 2 sites in Israel
- Volunteers
- 40 people
- Sponsor
- Medingo Ltd
Retinopathy of Prematurity (ROP)
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).
- Trial name
- PEDAL (NCT02386839)
- Testing
- rhIGF-1/rhIGFBP-3
- Where
- 16 sites in United States, Italy and 4 more
- Volunteers
- 76 people
- Sponsor
- Shire
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®
This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin…
- Trial name
- NCT01984372
- Testing
- insulin degludec
- Where
- Japan
- Volunteers
- 6,163 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Observational Study With InnoLet® in Daily Clinical Practice
This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492959
- Testing
- insulin human
- Where
- South Korea
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes
This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of adverse events while using Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00700765
- Testing
- insulin detemir
- Where
- Indonesia
- Volunteers
- 1,531 people
- Sponsor
- Novo Nordisk A/S
Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)
This is an intermediate-size patient population Early Access Program (EAP) providing access to intracerebroventricular (ICV) tralesinidase alfa (TA) for participants with mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo…
- Trial name
- EAP (NCT07733856)
- Testing
- Tralesinidase alfa (TA)
- Where
- United States
- Sponsor
- Spruce Biosciences
Diabetes, Diabetes Mellitus, Type 1
Surveillance Study of NovoRapid® for New Drug Re-examination
This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01490112
- Testing
- insulin aspart
- Where
- South Korea
- Volunteers
- 1,239 people
- Sponsor
- Novo Nordisk A/S
Noonan Syndrome
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) - insulin-like growth factor-I (IGF-I) axis resulting in low IGF-I levels have been suggested…
- Trial name
- NCT00351221
- Testing
- rhIGF-1/rhIGFBP-3
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Insmed Incorporated
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes
This study is conducted in Asia. The aim of this observational study is to evaluate the quality of life and clinical outcomes in subjects using NovoMix® 30 (biphasic insulin aspart 30) for the treatment of diabetes mellitus under…
- Trial name
- IMPROVE Life (NCT00696163)
- Testing
- biphasic insulin aspart 30
- Where
- India
- Volunteers
- 24,975 people
- Sponsor
- Novo Nordisk A/S
Intestinal Malabsorption
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants<3rd percentile* born at 26-32 weeks GA.
- Trial name
- NCT05904626
- Testing
- ELGN-2112
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Elgan Pharma Ltd.